Zobrazeno 1 - 10
of 3 045
pro vyhledávání: '"LAMONT, G."'
Autor:
Stocke K; Department of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry, 501 S. Preston St., Louisville, KY, 40292, USA., Lamont G; Department of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry, 501 S. Preston St., Louisville, KY, 40292, USA., Tan J; Department of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry, 501 S. Preston St., Louisville, KY, 40292, USA., Scott DA; Department of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry, 501 S. Preston St., Louisville, KY, 40292, USA. david.scott@louisville.edu.; Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, 40292, USA. david.scott@louisville.edu.
Publikováno v:
Scientific reports [Sci Rep] 2024 Sep 27; Vol. 14 (1), pp. 22247. Date of Electronic Publication: 2024 Sep 27.
Autor:
Hayhow TG; Oncology R&D, AstraZeneca, Cambridge, UK. thomas.hayhow@astrazeneca.com., Williamson B; Oncology R&D, AstraZeneca, Cambridge, UK., Lawson M; Oncology R&D, AstraZeneca, Cambridge, UK., Cureton N; Oncology R&D, AstraZeneca, Cambridge, UK., Braybrooke EL; Oncology R&D, AstraZeneca, Cambridge, UK., Campbell A; Pharmaceutical Sciences, AstraZeneca, Cambridge, UK., Carbajo RJ; Oncology R&D, AstraZeneca, Cambridge, UK., Cheraghchi-Bashi A; Oncology R&D, AstraZeneca, Cambridge, UK., Chiarparin E; Oncology R&D, AstraZeneca, Cambridge, UK., Diène CR; Oncology R&D, AstraZeneca, Cambridge, UK., Fallan C; Oncology R&D, AstraZeneca, Cambridge, UK., Fisher DI; Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Goldberg FW; Oncology R&D, AstraZeneca, Cambridge, UK., Hopcroft L; Oncology R&D, AstraZeneca, Cambridge, UK., Hopcroft P; Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Jackson A; Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Kettle JG; Oncology R&D, AstraZeneca, Cambridge, UK., Klinowska T; Oncology R&D, AstraZeneca, Cambridge, UK., Künzel U; Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Lamont G; Oncology R&D, AstraZeneca, Cambridge, UK., Lewis HJ; Oncology R&D, AstraZeneca, Cambridge, UK., Maglennon G; Oncology R&D, AstraZeneca, Cambridge, UK., Martin S; Oncology R&D, AstraZeneca, Cambridge, UK., Gutierrez PM; Oncology R&D, AstraZeneca, Cambridge, UK., Morrow CJ; Oncology R&D, AstraZeneca, Cambridge, UK., Nikolaou M; Oncology R&D, AstraZeneca, Cambridge, UK., Nissink JWM; Oncology R&D, AstraZeneca, Cambridge, UK., O'Shea P; Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Polanski R; Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Schade M; Oncology R&D, AstraZeneca, Cambridge, UK., Scott JS; Oncology R&D, AstraZeneca, Cambridge, UK., Smith A; Oncology R&D, AstraZeneca, Cambridge, UK., Weber J; Oncology R&D, AstraZeneca, Cambridge, UK., Wilson J; Oncology R&D, AstraZeneca, Cambridge, UK., Yang B; Oncology R&D, AstraZeneca, Waltham, MA, USA., Crafter C; Oncology R&D, AstraZeneca, Cambridge, UK.
Publikováno v:
Communications biology [Commun Biol] 2024 May 13; Vol. 7 (1), pp. 563. Date of Electronic Publication: 2024 May 13.
Autor:
Bao, Yicheng K.1, Weide, Lamont G.1, Ganesan, Vishwanath C.1, Jakhar, Ishaan1, Drees, Betty M.1, McGill, Janet B.2, Sahil, Suman3, Cheng, An‐Lin3, Gaddis, Monica3
Publikováno v:
Journal of Diabetes. Apr2019, Vol. 11 Issue 4, p273-279. 7p.
Autor:
Shields JD; Early Oncology R&D, AstraZeneca 35 Gatehouse Drive Waltham MA 02451 USA jason.shields@astrazeneca.com., Howells R; Early Oncology R&D, AstraZeneca 1 Francis Crick Avenue Cambridge CB2 0AA UK., Lamont G; Early Oncology R&D, AstraZeneca 1 Francis Crick Avenue Cambridge CB2 0AA UK., Leilei Y; Pharmaron Beijing Co., Ltd. 6 Taihe Road BDA Beijing 100176 P.R. China., Madin A; Discovery Sciences, AstraZeneca 1 Francis Crick Avenue Cambridge CB2 0AA UK., Reimann CE; Early Oncology R&D, AstraZeneca 35 Gatehouse Drive Waltham MA 02451 USA jason.shields@astrazeneca.com., Rezaei H; Early Oncology R&D, AstraZeneca 35 Gatehouse Drive Waltham MA 02451 USA jason.shields@astrazeneca.com., Reuillon T; Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca Pepparedsleden 1 43183 Mölndal Sweden., Smith B; Early Oncology R&D, AstraZeneca 1 Francis Crick Avenue Cambridge CB2 0AA UK., Thomson C; Early Oncology R&D, AstraZeneca 1 Francis Crick Avenue Cambridge CB2 0AA UK., Zheng Y; Pharmaron Beijing Co., Ltd. 6 Taihe Road BDA Beijing 100176 P.R. China., Ziegler RE; Early Oncology R&D, AstraZeneca 35 Gatehouse Drive Waltham MA 02451 USA jason.shields@astrazeneca.com.
Publikováno v:
RSC medicinal chemistry [RSC Med Chem] 2024 Feb 16; Vol. 15 (4), pp. 1085-1095. Date of Electronic Publication: 2024 Feb 16 (Print Publication: 2024).
Publikováno v:
Journal of Information Warfare, 2003 Jan 01. 2(1), 1-14.
Externí odkaz:
https://www.jstor.org/stable/26486884
Autor:
Charles W. Van Way, Ray Segebrecht, Ashley Bennett, Douglas Geehan, Michael Moncure, Lamont G. Weide
Publikováno v:
Journal of Parenteral and Enteral Nutrition. 43:937-940
Diabetic ketoacidosis is defined as hyperglycemia >250 mg/dL with metabolic acidosis of arterial pH 10. Euglycemic ketoacidosis has been reported in patients with type 2 diabetes and in patients with type 1 diabetes. However, as a surgical complicati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3270fb7361b017f9fda158ceeced0be
https://doi.org/10.1002/jpen.1594
https://doi.org/10.1002/jpen.1594
Publikováno v:
In The Foot 2007 17(4):214-217
Autor:
Lamont G Weide, Sean Mccalmon
Publikováno v:
Journal of the Endocrine Society
Background: Antipsychotic medications come with an array of potential side effects in a difficult-to-treat population, particularly if management of other comorbidities is required. A review of the literature shows some studies have discussed the pos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a7aa74e69aaf1911ad5013e642f514b
http://europepmc.org/articles/PMC8265833
http://europepmc.org/articles/PMC8265833
Autor:
Kettle JG; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Bagal SK; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Bickerton S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Bodnarchuk MS; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Boyd S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Breed J; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Carbajo RJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Cassar DJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Chakraborty A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Cosulich S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Cumming I; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Davies M; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Davies NL; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Eatherton A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Evans L; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Feron L; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Fillery S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Gleave ES; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Goldberg FW; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Hanson L; Oncology R&D, AstraZeneca, Alderley Park SK10 4TG, U.K., Harlfinger S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Howard M; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Howells R; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Jackson A; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Kemmitt P; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Lamont G; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Lamont S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Lewis HJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Liu L; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China., Niedbala MJ; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Phillips C; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Polanski R; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Raubo P; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Robb G; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Robinson DM; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Ross S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Sanders MG; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Tonge M; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Whiteley R; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Wilkinson S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Yang J; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China., Zhang W; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2022 May 12; Vol. 65 (9), pp. 6940-6952. Date of Electronic Publication: 2022 Apr 26.
Autor:
An-Lin Cheng, Vishwanath C. Ganesan, Yicheng K. Bao, Suman Sahil, Monica Gaddis, Ishaan Jakhar, Janet B. McGill, Betty M. Drees, Lamont G. Weide
Publikováno v:
Journal of diabetes. 11(4)
Patients with type 1 diabetes (T1D) are at risk for other autoimmune diseases (ie, polyautoimmunity). The prevalence and risk factors of this phenomenon have been underreported in adults and ethnic minorities, and data are lacking regarding non-endoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e872c031c5cd6f50124cafde236be0a
https://pubmed.ncbi.nlm.nih.gov/30226016
https://pubmed.ncbi.nlm.nih.gov/30226016